Newsfeed

Bei diesem Bereich handelt es sich um eine mögliche Darstellungsform der Integration von Nachrichtenquellen mit Bezug zu börsennotierten Unternehmen.
Als Präsentationsebene fungiert ein Template, dass an Kurznachrichtenservices angelehnt ist, bei dem sich Nutzer einen schnellen Überblick über aktuelle Nachrichten verschaffen können. Die Detailansichten ermöglichen bei Interesse weitergehende Recherchen.

Dieser Newsfeed ist eine Zusammenstellung aktueller Nachrichten, die aus Direktanbindungen von TopTier NewsWire-Services mit Bezug zu börsennotierten Unternehmen stammen. Dieser Feed hier dient ausschließlich Demonstrationszwecken. Sektoren-spezifische Nachrichten, Public Relations sowie Produktinformationen können über die GICS Portale > Bereich Sektor-Intelligence abgerufen werden.

US2546041011
Filter zurücksetzen
Do you already know our new terminal view? Click here.
FIGI: BBG00W9MJK79
IRON
Disc Medicine Inc
GICS: Health Care · SECTOR: Healthcare · SUB-SECTOR: Biotechnology · THEMEFOLIO: $HLTH
NAME
Disc Medicine Inc
ISIN
US2546041011
TICKER
IRON
MIC
XNAS
REUTERS
IRON.OQ
BLOOMBERG
IRON US
Mo., 27.04.2026       Disc Medicine
US2546041011

New York, New York--(Newsfile Corp. - April 26, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON) resulting from allegations that Disc Medicine may have issued materially misleading business information to the inve...
Zur Nachricht
Disc Medicine
Charts & Research Termsheets Terminal
Permalink
Sa., 25.04.2026       Disc Medicine
US2546041011

NEW YORK, April 25, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON) resulting from alleg...
Zur Nachricht
Disc Medicine
Charts & Research Termsheets Terminal
Permalink
Mi., 22.04.2026       Disc Medicine
US2546041011

New York, New York--(Newsfile Corp. - April 21, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON) resulting from allegations that Disc Medicine may have issued materially misleading business information to the investing...
Zur Nachricht
Disc Medicine
Charts & Research Termsheets Terminal
Permalink
Di., 21.04.2026       Disc Medicine
US2546041011

WATERTOWN, Mass., April 21, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced that it will present data from the RALLY-MF Phase 2 trial of D...
Zur Nachricht
Disc Medicine
Charts & Research Termsheets Terminal
Permalink
Di., 21.04.2026       Disc Medicine
US2546041011

New York, New York--(Newsfile Corp. - April 20, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON) resulting from allegations that Disc Medicine may have issued materially misleading business information to the inve...
Zur Nachricht
Disc Medicine
Charts & Research Termsheets Terminal
Permalink
Do., 16.04.2026       Disc Medicine
US2546041011

NEW YORK, April 16, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Disc Medicine, Inc. ("Disc" or the "Company") (NASDAQ: IRON). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Zur Nachricht
Disc Medicine
Charts & Research Termsheets Terminal
Permalink
Di., 14.04.2026       Disc Medicine
US2546041011

NEW YORK, April 14, 2026 /PRNewswire/ --  Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON) resulting from alle...
Zur Nachricht
Disc Medicine
Charts & Research Termsheets Terminal
Permalink
Sa., 11.04.2026       Disc Medicine
US2546041011

New York, New York--(Newsfile Corp. - April 10, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON) resulting from allegations that Disc Medicine may have issued materially misleading business information to the investing...
Zur Nachricht
Disc Medicine
Charts & Research Termsheets Terminal
Permalink
Do., 09.04.2026       Disc Medicine
US2546041011

NEW YORK, April 9, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON) resulting from allega...
Zur Nachricht
Disc Medicine
Charts & Research Termsheets Terminal
Permalink
Do., 09.04.2026       Disc Medicine
US2546041011

NEW YORK, April 9, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Disc Medicine, Inc. ("Disc" or the "Company") (NASDAQ: IRON). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Zur Nachricht
Disc Medicine
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Mo., 06.04.2026       Disc Medicine
US2546041011

New York, New York--(Newsfile Corp. - April 6, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Disc Medicine, Inc. (NASDAQ: IRON) ("Disc Medicine, Inc.") concerning potential violations of the federal securities laws.On February 13, 2026, Disc disclosed that the FDA had issued a Complete Respons...
Zur Nachricht
Disc Medicine
Charts & Research Termsheets Terminal
Permalink
Do., 02.04.2026       Disc Medicine
US2546041011

NEW YORK, April 2, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Disc Medicine, Inc. ("Disc" or the "Company") (NASDAQ: IRON).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.  ...
Zur Nachricht
Disc Medicine
Charts & Research Termsheets Terminal
Permalink
Mi., 01.04.2026       Disc Medicine
US2546041011

Investigation examines gap between reported figures and GAAP results at Disc Medicine ahead of its 21.9% stock collapse NEW YORK, April 1, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP is investigating whether Disc Medicine, Inc. (NASDAQ: IRON) and certain of its officers fulfilled their disclosure obligations to investors in the period leading...
Zur Nachricht
Disc Medicine
Charts & Research Termsheets Terminal
Permalink
Mo., 30.03.2026       Disc Medicine
US2546041011

NEW YORK, March 30, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON) resulting from alleg...
Zur Nachricht
Disc Medicine
Charts & Research Termsheets Terminal
Permalink
Mo., 30.03.2026       Disc Medicine
US2546041011

New York, New York--(Newsfile Corp. - March 30, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Disc Medicine, Inc. ("Disc Medicine, Inc.") (NASDAQ: IRON) concerning potential violations of the federal securities laws.On February 13, 2026, Disc disclosed that the FDA had issued a Complete Response Letter...
Zur Nachricht
Disc Medicine
Charts & Research Termsheets Terminal
Permalink
Mo., 30.03.2026       Disc Medicine
US2546041011

New York, New York--(Newsfile Corp. - March 29, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON) resulting from allegations that Disc Medicine may have issued materially misleading business information to the inve...
Zur Nachricht
Disc Medicine
Charts & Research Termsheets Terminal
Permalink
So., 29.03.2026       Disc Medicine
US2546041011

New York, New York--(Newsfile Corp. - March 28, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON) resulting from allegations that Disc Medicine may have issued materially misleading business information to the...
Zur Nachricht
Disc Medicine
Charts & Research Termsheets Terminal
Permalink
Do., 26.03.2026       Disc Medicine
US2546041011

WATERTOWN, Mass., March 26, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced that the last participant has been randomized and dosed in the...
Zur Nachricht
Disc Medicine
Charts & Research Termsheets Terminal
Permalink
Do., 26.03.2026       Disc Medicine
US2546041011

New York, New York--(Newsfile Corp. - March 26, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON) resulting from allegations that Disc Medicine may have issued materially misleading business information to the inve...
Zur Nachricht
Disc Medicine
Charts & Research Termsheets Terminal
Permalink
Do., 26.03.2026       Disc Medicine
US2546041011

NEW YORK, March 26, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Disc Medicine, Inc. ("Disc" or the "Company") (NASDAQ: IRON). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Zur Nachricht
Disc Medicine
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Mi., 25.03.2026       Disc Medicine
US2546041011

Investigation examines gap between reported figures and GAAP results at Disc Medicine ahead of its 21.9% stock collapse NEW YORK, March 25, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP is investigating whether Disc Medicine, Inc. (NASDAQ: IRON) and certain of its officers fulfilled their disclosure obligations to investors in the period leading...
Zur Nachricht
Disc Medicine
Charts & Research Termsheets Terminal
Permalink
Mo., 23.03.2026       Disc Medicine
US2546041011

New York, New York--(Newsfile Corp. - March 23, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON) resulting from allegations that Disc Medicine may have issued materially misleading business information to the inve...
Zur Nachricht
Disc Medicine
Charts & Research Termsheets Terminal
Permalink
Mo., 23.03.2026       Disc Medicine
US2546041011

New York, New York--(Newsfile Corp. - March 23, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Disc Medicine, Inc. (NASDAQ: IRON) ("Disc Medicine, Inc.") concerning potential violations of the federal securities laws.On February 13, 2026, Disc disclosed that the FDA had issued a Complete Respon...
Zur Nachricht
Disc Medicine
Charts & Research Termsheets Terminal
Permalink
So., 22.03.2026       Disc Medicine
US2546041011

New York, New York--(Newsfile Corp. - March 22, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces that it is investigating potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON) resulting from allegations that Disc Medicine may have issued materially misleading business information to the...
Zur Nachricht
Disc Medicine
Charts & Research Termsheets Terminal
Permalink
Fr., 20.03.2026       Disc Medicine
US2546041011

NEW YORK, March 20, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces that it is investigating potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON) resulting...
Zur Nachricht
Disc Medicine
Charts & Research Termsheets Terminal
Permalink
Do., 19.03.2026       Disc Medicine
US2546041011

Why: Rosen Law Firm, a global investor rights law firm, announces that it is investigating potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON) resulting from allegations that Disc Medicine may have issued materially misleading business information to the investing public. So What: If you purchased Disc Med...
Zur Nachricht
Disc Medicine
Charts & Research Termsheets Terminal
Permalink
Mi., 18.03.2026       Disc Medicine
US2546041011

New York, New York--(Newsfile Corp. - March 18, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Disc Medicine, Inc. ("Disc Medicine, Inc.") (NASDAQ: IRON) concerning potential violations of the federal securities laws.On February 13, 2026, Disc disclosed that the FDA had issued a Complete Response Letter...
Zur Nachricht
Disc Medicine
Charts & Research Termsheets Terminal
Permalink
Mi., 18.03.2026       Disc Medicine
US2546041011

Disc Medicine investors who lost money after the FDA issued a Complete Response Letter for bitopertin are encouraged to contact Levi & KorsinskyNEW YORK, March 18, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP is investigating Disc Medicine, Inc. (NASDAQ: IRON) regarding whether the company adequately communicated risks regarding its bitopert...
Zur Nachricht
Disc Medicine
Charts & Research Termsheets Terminal
Permalink
Sa., 14.03.2026       Disc Medicine
US2546041011

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Disc Medicine, Inc. (“Disc” or “the Company”) (NASDAQ: IRON) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to dis...
Zur Nachricht
Disc Medicine
Charts & Research Termsheets Terminal
Permalink
Mi., 11.03.2026       Disc Medicine
US2546041011

Investigation examines gap between reported figures and GAAP results at Disc Medicine ahead of its 21.9% stock collapseNEW YORK, March 11, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP is investigating whether Disc Medicine, Inc. (NASDAQ: IRON) and certain of its officers fulfilled their disclosure obligations to investors in the period leading u...
Zur Nachricht
Disc Medicine
Charts & Research Termsheets Terminal
Permalink
Mi., 04.03.2026       Disc Medicine
US2546041011

New York, New York--(Newsfile Corp. - March 4, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Disc Medicine, Inc. ("Disc Medicine, Inc.") (NASDAQ: IRON) concerning potential violations of the federal securities laws.On February 13, 2026, Disc disclosed that the FDA had issued a Complete Response Letter (...
Zur Nachricht
Disc Medicine
Charts & Research Termsheets Terminal
Permalink
Do., 26.02.2026       Disc Medicine
US2546041011

NEW YORK, Feb. 26, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Disc Medicine, Inc. ("Disc" or the "Company") (NASDAQ: IRON). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Zur Nachricht
Disc Medicine
Charts & Research Termsheets Terminal
Permalink
Do., 26.02.2026       Disc Medicine
US2546041011

WATERTOWN, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today reported financial results for the fourth quarter and full year ended Dec...
Zur Nachricht
Disc Medicine
Charts & Research Termsheets Terminal
Permalink
Fr., 20.02.2026       Disc Medicine
US2546041011

NEW YORK, Feb. 19, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Disc Medicine, Inc. ("Disc" or the "Company") (NASDAQ: IRON).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Zur Nachricht
Disc Medicine
Charts & Research Termsheets Terminal
Permalink
Fr., 13.02.2026       Disc Medicine
US2546041011

WATERTOWN, Mass., Feb. 13, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced that the U.S. Food and Drug Administration (FDA) today issued a Complete Response Le...
Zur Nachricht
Disc Medicine
Charts & Research Termsheets Terminal
Permalink
Fr., 13.02.2026       Disc Medicine
US2546041011

NEW YORK, Feb. 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Disc Medicine, Inc. ("Disc" or the "Company") (NASDAQ: IRON). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Zur Nachricht
Disc Medicine
Charts & Research Termsheets Terminal
Permalink
Do., 29.01.2026       Disc Medicine
US2546041011

NEW YORK, Jan. 29, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Disc Medicine, Inc. ("Disc" or the "Company") (NASDAQ: IRON). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Zur Nachricht
Disc Medicine
Charts & Research Termsheets Terminal
Permalink
Mo., 12.01.2026       Disc Medicine
US2546041011

WATERTOWN, Mass., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the appointment of Lisa Amaya Price, MBA as the company’s Chief...
Zur Nachricht
Disc Medicine
Charts & Research Termsheets Terminal
Permalink
Mo., 12.01.2026       Disc Medicine
US2546041011

WATERTOWN, Mass., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today outlined its recent pipeline progress and strategic priorities for 2026....
Zur Nachricht
Disc Medicine
Charts & Research Termsheets Terminal
Permalink
Mi., 07.01.2026       Disc Medicine
US2546041011

WATERTOWN, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that John Quisel, J.D., Ph.D., President and Chief Executive Of...
Zur Nachricht
Disc Medicine
Charts & Research Termsheets Terminal
Permalink
Sa., 06.12.2025       Disc Medicine
US2546041011

WATERTOWN, Mass., Dec. 06, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today presented positive initial data from the RALLY-MF Phase 2 trial of DISC-0...
Zur Nachricht
Disc Medicine
Charts & Research Termsheets Terminal
Permalink
Do., 06.11.2025       Disc Medicine
US2546041011

WATERTOWN, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today reported financial results for the third quarter ended September 30, 2025...
Zur Nachricht
Disc Medicine
Charts & Research Termsheets Terminal
Permalink
Fr., 31.10.2025       Disc Medicine
US2546041011

WATERTOWN, Mass., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that company management will participate in fireside chats at t...
Zur Nachricht
Disc Medicine
Charts & Research Termsheets Terminal
Permalink
Di., 21.10.2025       Disc Medicine
US2546041011

WATERTOWN, Mass., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the pricing of the upsized underwritten offering of sha...
Zur Nachricht
Disc Medicine
Charts & Research Termsheets Terminal
Permalink
Fr., 17.10.2025       Disc Medicine
US2546041011

WATERTOWN, Mass., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced it will present clinical data as a poster presentation at the u...
Zur Nachricht
Disc Medicine
Charts & Research Termsheets Terminal
Permalink
Do., 16.10.2025       Disc Medicine
US2546041011

WATERTOWN, Mass., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced that it received a Commissioner’s National Priority Voucher (CN...
Zur Nachricht
Disc Medicine
Charts & Research Termsheets Terminal
Permalink
Di., 30.09.2025       Disc Medicine
US2546041011

WATERTOWN, Mass., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the submission of a New Drug Application (NDA) to the U.S. Foo...
Zur Nachricht
Disc Medicine
Charts & Research Termsheets Terminal
Permalink
Do., 07.08.2025       Disc Medicine
US2546041011

WATERTOWN, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today reported financial results for the second quarter ended June 30, 2025, an...
Zur Nachricht
Disc Medicine
Charts & Research Termsheets Terminal
Permalink
Mi., 14.05.2025       Disc Medicine
US2546041011

WATERTOWN, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced that it will present data from multiple programs in its hematolo...
Zur Nachricht
Disc Medicine
Charts & Research Termsheets Terminal
Permalink
Mi., 07.05.2025       Disc Medicine
US2546041011

WATERTOWN, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today reported financial results for the first quarter ended March 31, 2025, and...
Zur Nachricht
Disc Medicine
Charts & Research Termsheets Terminal
Permalink